Stock Information
symbol line chart

HIMSHims & Hers Health Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Andrew Dudum

Location

California, USA

Exchange

NYSE

Website

https://forhims.com

Summary

Hims & Hers Health, Inc.

Company Info

CEO

Andrew Dudum

Location

California, USA

Exchange

NYSE

Website

https://forhims.com

Summary

Hims & Hers Health, Inc.

AI Insights for HIMS
2 min read

Quick Summary

Hims & Hers Health Inc is a United States-based telehealth company focused on delivering health and wellness services directly to consumers through a digital platform. The company operates a multi-specialty telehealth ecosystem connecting users with licensed healthcare professionals for medical consultations and ongoing care. Their offerings include both prescription and non-prescription products addressing wellness, hair loss, mental health, sexual health, and more. The business leverages online platforms to provide convenient access to medical expertise and curated wellness products, with an expanding focus on newer medications such as GLP-1s for weight management. Hims & Hers primarily targets health-conscious adults seeking accessible, affordable healthcare solutions without traditional in-person visits.

The Bull Case

  • Hims & Hers boasts strong brand recognition in the burgeoning telehealth sector, with a highly accessible digital platform that attracts a large and rapidly growing subscriber base.
  • Its diversified product lineup encompasses both wellness and prescription segments, offering cross-selling opportunities.
  • The company has demonstrated significant top-line and net income growth, reflecting effective execution and scalability.
  • Its nimble approach allows for quick adaptation to new health trends, such as GLP-1 weight-loss drugs, and a strong direct-to-consumer marketing capability.
  • Additionally, Hims & Hers maintains a debt-free balance sheet and robust cash generation, providing operational flexibility.

The Bear Case

  • Despite strong growth, Hims & Hers is highly sensitive to regulatory changes, as recent issues with compounded GLP-1 products show.
  • The company’s high price-to-earnings and enterprise value multiples indicate lofty market expectations, exposing shares to sharp corrections on any disappointment.
  • Its business model is still reliant on a narrow range of therapeutic areas, with GLP-1s disproportionately influencing investor perceptions.
  • Leadership turnover, as highlighted by the recent COO departure, may create uncertainty internally and externally.
  • Lastly, while expanding, the company faces scalability and compliance risks as it diversifies its offerings.

Key Risks

  • Key risks include greater regulatory scrutiny of compounded medications, such as those for weight loss, which could limit certain product lines and invite legal or financial penalties.
  • Competitive pressure from well-capitalized players like Amazon and CVS Health may erode market share or compress margins.
  • High valuation leaves the stock vulnerable to negative surprises in earnings or subscriber growth.
  • Disruptive executive turnover and potential misalignment around strategic direction could hamper execution.

What to Watch

UpcomingIn the most recent quarter, Hims & Hers reported strong revenue growth, with year-over-year revenue rising 49% to nearly $600 million, and net income reaching $15.8 million.
UpcomingThe company added 21% more subscribers, totaling 2.47 million.
UpcomingKey events included ongoing negotiations with Novo Nordisk over Wegovy distribution and a controversial leadership change: COO Nader Kabbani stepped down, succeeded by Mike Chi, affecting investor sentiment.
ExpectedFor the coming quarter, Hims & Hers is expected to continue its rapid growth trajectory, as suggested by its raised full-year revenue guidance of $2.335B-$2.355B and targeted adjusted EBITDA of $307M-$317M.

Price Drivers

  • The stock price of Hims & Hers Health is influenced by several key factors.
  • Earnings growth, especially the pace of revenue and net income expansion, greatly affect investor sentiment and valuation multiples.
  • News around regulatory developments, particularly regarding the sale of compounded GLP-1 drugs for weight loss, can cause significant volatility.
  • Leadership changes and strategic decisions, such as expansion plans or discontinued partnerships (like the terminated Wegovy deal with Novo Nordisk), also play a central role.

Recent News

  • Recent news about Hims & Hers Health Inc has been dominated by volatility stemming from both market and company-specific events.
  • The company experienced sharp stock swings related to regulatory decisions over its compounded GLP-1 offerings and the termination of its partnership with Novo Nordisk for Wegovy.
  • A major executive reshuffle occurred, with COO Nader Kabbani departing and being replaced by Mike Chi, raising both optimism and concern among analysts and investors.
  • Despite setbacks, analysts have increased price targets, while some firms, such as BofA, maintain a cautious outlook, highlighting risks tied to semaglutide products.

Market Trends

  • Broader market trends influencing Hims & Hers include the rapid adoption of telehealth platforms, increased consumer comfort with digital health management, and the growing demand for wellness and weight-loss products.
  • Regulatory oversight is tightening, especially for compounded pharmaceuticals, raising compliance challenges across the sector.
  • Analysts note that the convergence of healthcare delivery and technology is attracting both new entrants and large incumbents, intensifying competition.
  • Macro trends like inflation, healthcare spending shifts, and possible changes in insurance reimbursement may alter demand dynamics.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on HIMS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Shashaa 2 weeks ago

US FDA is expected to lift restriction on certain peptides, NYT reports

US FDA is expected to lift restriction on certain peptides, NYT reports

has been planning on this peptide play since last year. There was a 14% gain when RJK mentioned in on Joe Rogan podcast. Now that NYT reported it is going to happens, it gapped up 8% within one hours already



avatar
@Simonwhite 3 weeks ago

Hims & Hers Health growing global footprint

Hims & Hers Health growing global footprint

it's pretty wild to see how fast hims & hers health is moving with this eucalyptus acquisition. i'm curious if the upgrades from barclays and leerink are enough to keep the momentum going or if the integration will take some time. what are you all thinking about their global expansion strategy?

avatar
@democratiCrayn 1 month ago

Canaccord cuts HIMS target to $30 after Novo Nordisk lawsuit

Canaccord cuts HIMS target to $30 after Novo Nordisk lawsuit

post thumbnail

finance.yahoo.com

| Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny

avatar
@General-Mils 1 month ago

HIMS down 50% YTD on GLP-1 issues and weak guidance

HIMS down 50% YTD on GLP-1 issues and weak guidance

post thumbnail

www.fool.com

| Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? | The Motley Fool

avatar
@JaneWilliams 1 month ago

$HIMS: Is This a Turning Point or More Pain?

$HIMS: Is This a Turning Point or More Pain?

Not gonna lie, Hims & Hers Health feels messy right now. The growth story is still there, but between heavy marketing spend, legal noise, and all the GLP-1 drama tied to Novo Nordisk, it’s hard to know what actually matters most.

The Eucalyptus deal sounds exciting, but big acquisitions always come with questions.

This feels like one of those moments where sentiment could flip fast either way. Are people betting on a real long-term brand, or was the weight-loss wave the main driver?

avatar
@Simonwhite 1 month ago

Big expansion for Hims & Hers Health

Big expansion for Hims & Hers Health

i'm really curious to see how the eucalyptus acquisition will impact the long-term growth for , especially with these new analyst upgrades. do you think the insider selling is something to worry about right now, or is that $48 price target more realistic? i'd love to hear what everyone else thinks about their global strategy.

avatar
@ShallowLoving 2 months ago

YieldMax announced distributions for Group 2 weekly ETFs

YieldMax announced distributions for Group 2 weekly ETFs

post thumbnail

markets.businessinsider.com

| YieldMax® ETFs Announces Weekly Distributions for Group 2 ETFs

avatar
@Altruistic_Dr2 2 months ago

Market recap: Dow hits 50k, APP surges, and KD gets crushed

Market recap: Dow hits 50k, APP surges, and KD gets crushed

post thumbnail

www.investopedia.com

| Markets News, Feb. 9, 2026: Major Indexes Close Higher to Begin Week; Tech Stocks Power Nasdaq, S&P 500; Dow Hits New All-Time High

avatar
@starcahier 2 months ago

Market recap: Dow hits 50k, Tech rebounds, Amazon slides

Market recap: Dow hits 50k, Tech rebounds, Amazon slides

post thumbnail

finance.yahoo.com

| Stock market today: Dow closes above 50,000 for the first time as stocks soar to cap volatile week

avatar
@General-Mils 2 months ago

HIMS drops 12% after hours following FDA warning on compounded GLP-1s

HIMS drops 12% after hours following FDA warning on compounded GLP-1s

post thumbnail

finance.yahoo.com

| FDA scrutiny rattles Hims & Hers stock